Direct neuronal infection of SARS-CoV-2 reveals cellular and molecular pathology of chemosensory impairment of COVID-19 patients

Emerg Microbes Infect. 2022 Dec;11(1):406-411. doi: 10.1080/22221751.2021.2024095.

Abstract

Patients with recent pandemic coronavirus disease 19 (COVID-19) complain of neurological abnormalities in sensory functions such as smell and taste in the early stages of infection. Determining the cellular and molecular mechanism of sensory impairment is critical to understand the pathogenesis of clinical manifestations, as well as in setting therapeutic targets for sequelae and recurrence. The absence of studies utilizing proper models of human peripheral nerve hampers an understanding of COVID-19 pathogenesis. Here, we report that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly infects human peripheral sensory neurons, leading to molecular pathogenesis for chemosensory impairments. An in vitro system utilizing human embryonic stem cell (hESC)-derived peripheral neurons was used to model the cellular and molecular pathologies responsible for symptoms that most COVID-19 patients experience early in infection or may develop as sequelae. Peripheral neurons differentiated from hESCs expressed viral entry factor ACE2, and were directly infected with SARS-CoV-2 via ACE2. Human peripheral neurons infected with SARS-CoV-2 exhibited impaired molecular features of chemosensory function associated with abnormalities in sensory neurons of the olfactory or gustatory organs. Our results provide new insights into the pathogenesis of chemosensory dysfunction in patients with COVID-19.

Keywords: SARS-CoV-2; chemosensory impairment; hESC-derived peripheral neurons; infection modelling; viral infection.

Publication types

  • Letter

MeSH terms

  • Angiotensin-Converting Enzyme 2 / physiology
  • COVID-19 / complications*
  • Humans
  • Olfaction Disorders / etiology*
  • SARS-CoV-2*
  • Sensory Receptor Cells / virology*
  • Taste Disorders / etiology*

Substances

  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2

Grants and funding

Work in the Kim lab was supported by the National Research Foundation of Korea (NRF-2017R1C1B3009321 and NRF-2017M3C7A1047640). Work in the Yun lab was supported by the National Research Foundation of Korea (NRF-2019R1I1A3A01061034) and the grant from Institute of Health Sciences of Gyeongsang National University (IHS GNU-2019-01).